Polaryx Therapeutics

What Polaryx Therapeutics does

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Paramus, New Jersey, developing patient-friendly small molecule and gene therapy treatments for rare pediatric lysosomal storage disorders (LSDs). Founded in 2014 and listed on Nasdaq Capital Market under ticker PLYX via direct listing on February 2, 2026, the company is controlled by Mstone Healthcare Partners (an entity affiliated with CEO and Chair Alex Yang). The pipeline is anchored by PLX-200, a reformulated oral solution of gemfibrozil pursued under a 505(b)(2) regulatory pathway; PLX-200 acts as a PPARα agonist that upregulates Transcription Factor EB (TFEB) to promote lysosomal biogenesis, reduce neuroinflammation, and support neuronal survival. Supporting candidates include PLX-100 (PPARα + RXRα vitamin A combination), PLX-300 (cinnamic-acid-based combination for GM2/Niemann-Pick A/B/Krabbe), and PLX-400 (intranasally administered AAV gene therapy). The lead asset is being evaluated in the FDA-cleared SOTERIA Phase 2 basket trial across CLN2, CLN3, Krabbe disease, and Sandhoff disease (~25% of the LSD population), and in the IND-approved STARLIGHT Phase 3 registrable trial for CLN3 (NCT04637282).

Polaryx has accumulated a regulatory exclusivity layer including FDA Orphan Drug Designation across multiple LSDs, EMA Orphan Drug Designation for PLX-200 in all NCL subtypes, Rare Pediatric Disease Designations for PLX-300, and FDA Fast Track Designation completed across all four SOTERIA indications in March–April 2026. The company is pre-revenue; it closed a $10 million PIPE financing on May 28, 2026 to fund the SOTERIA trial and extend operating runway through Q2 2027, and is explicitly seeking strategic pharmaceutical and commercialization partners for future launch. Operations are conducted through a lean leadership team (11–50 employees) supplemented by a contract research organization executing the multi-geography SOTERIA trial across the U.S., Europe, and Asia.

The business model is pre-commercial: no product revenue, with future revenue expected from prescription drug sales or licensing of PLX-200 if approved. Pricing details are not publicly disclosed. The company engages patient advocacy organizations (NTSAD, Krabbe disease community) for outreach and uses scientific/investor conferences and press-release distribution channels for stakeholder communications. End-customers upon commercialization would be pediatric patients with CLN2, CLN3, Krabbe, and Sandhoff diseases, served via prescription drug distribution (likely through a commercialization partner rather than direct sales infrastructure given current headcount).

Name

Polaryx Therapeutics

Legal name

Polaryx Therapeutics, Inc.

Website

https://polaryx.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Polaryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule (PPARα agonist PLX-200) and AAV gene therapy treatments for rare pediatric lysosomal storage disorders including CLN2, CLN3, Krabbe, and Sandhoff diseases, listed on Nasdaq as PLYX.

Ownership category

akta.pro rank

Product category

Lysosomal Storage Disorder Therapeutics

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Rare disease therapeutics
• Lysosomal storage disorders
• Small molecule drug development
• Gene therapy pipeline
• Clinical-stage biotechnology

Headquarters

HQ city

Paramus

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-revenue Clinical Development Stage: Polaryx is a clinical-stage biotechnology company with no commercial product revenue. The company is funded by equity financings (e.g., $10 million PIPE in May 2026) and would generate future revenue from prescription drug sales (likely one-time license/prescription sales) of PLX-200 if approved. The company is also seeking commercialization partners.
2. Equity Financing (PIPE): Closed a $10 million Private Investment in Public Equity (PIPE) financing on May 28, 2026, consisting of 2,502,696 shares of common stock at approximately $4.00 per share to fund the Phase 2 SOTERIA trial and extend operating runway through Q2 2027.

Go-to-market motion4 records

Core offering

Polaryx Therapeutics is developing patient-friendly small molecule and gene therapy drug candidates for rare pediatric lysosomal storage disorders. Its lead clinical asset PLX-200 is an oral reformulation of gemfibrozil pursued under a 505(b)(2) regulatory pathway, with a pipeline of preclinical candidates (PLX-100, PLX-300, PLX-400) and active clinical programs including the SOTERIA Phase 2 basket trial and STARLIGHT Phase 3 trial.

Product overview

Polaryx Therapeutics is a clinical-stage biotechnology company with a multi-modal, platform-style pipeline of patient-friendly small molecule and gene therapy candidates targeting rare pediatric lysosomal storage disorders (LSDs). The core platform centers on PPARα-driven TFEB upregulation to promote lysosomal biogenesis, and is anchored by its lead clinical asset PLX-200 (an oral, reformulated gemfibrozil), which is being evaluated in the IND-approved SOTERIA Phase 2 basket trial and the IND-approved STARLIGHT Phase 3 trial. Supporting the lead asset are preclinical candidates PLX-100 (a PLX-200 + vitamin A combination), PLX-300 (cinnamic-acid-based combination), and PLX-400 (an AAV-based gene therapy), together with single-pivotal-trial programs in CLN2 and CLN3. The company was founded in 2014, listed on Nasdaq via direct listing in February 2026, and is headquartered in Paramus, NJ.

Differentiator

Problem solved

Functional benefit

Products and services

• PLX-200 PLX-200 is a reformulated oral small molecule (derived from gemfibrozil) administered as a proprietary patient-friendly oral solution. It acts as a PPARα agonist that upregulates Transcription Factor EB (TFEB) to promote lysosomal biogenesis, reduce brain inflammation, and promote neuronal survival in lysosomal storage disorder models. It is being advanced through the IND-approved Phase 2 SOTERIA basket trial across CLN2, CLN3, Krabbe disease, and Sandhoff disease.
• PLX-100 PLX-100 is a preclinical-stage, orally administrable combination therapy composed of the PPARα agonist PLX-200 and vitamin A (an RXRα agonist). It has demonstrated neuroprotective effects in murine CLN2 and CLN3 disease models, extended lifespan in CLN2 models, and reduced brain lipofuscin accumulation, providing dual nuclear receptor activation for enhanced neuroprotection.
• PLX-300 PLX-300 is a preclinical-stage, orally administrable combination therapy composed of an unsaturated carboxylic acid and a PPARα agonist (cinnamic acid as the main component, occurring naturally in plants as a deaminated product of phenylalanine). It exhibits antioxidant and anti-inflammatory activities that protect brain cells from neurodegeneration.
• PLX-400 PLX-400 is a preclinical-stage novel gene therapy candidate designed to deliver lysosomal genes via adeno-associated viral (AAV) vectors. Initial development is focused on CLN2 and CLN3. The candidate is being explored as a monotherapy or in combination with oral PLX-200, with intranasal administration. Preclinical studies in murine models have shown increased lifespan.
• SOTERIA Phase 2 Basket Trial SOTERIA is a small-scale, proof-of-concept, open-label Phase 2 basket trial designed to assess the safety, tolerability, and clinical activity of PLX-200 across four lysosomal storage disorders — CLN2, CLN3, Krabbe disease, and Sandhoff disease — which together represent approximately one quarter of the LSD patient population. Operates with up to four arms (one per indication) that can be managed as a single trial via Bayesian methods.
• STARLIGHT Phase 3 Trial (CLN3) STARLIGHT is an IND-approved Phase 3, randomized, double-blind, placebo-controlled registrable trial of PLX-200 for the treatment of mild-to-moderate CLN3 disease. Primary endpoints evaluate safety/tolerability and efficacy using the motor score of the Hamburg Rating Scale after 60 weeks of maintenance therapy. Listed on ClinicalTrials.gov as NCT04637282.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cyclo Therapeutics: Clinical-stage company developing Trappsol Cyclo (hydroxypropyl beta cyclodextrin) for Niemann-Pick disease type C and other LSDs. Direct competitor targeting adjacent LSD indications with a repurposed small molecule approach similar to Polaryx's strategy.
• Regenxbio: Developing ABO-202, an AAV gene therapy for CLN2 and CLN3, directly overlapping with Polaryx's PLX-200 and PLX-400 programs. Comparable rare pediatric CNS gene therapy developer with substantially greater capital resources.
• Taysha Gene Therapies: Clinical-stage gene therapy company targeting CLN1 (Batten disease) and other rare CNS disorders. Competes in the same neuronal ceroid lipofuscinosis therapeutic category with an AAV-based delivery approach.
• BioMarin Pharmaceutical: BioMarin markets Brineura (cerliponase alfa), the only FDA-approved enzyme replacement therapy for CLN2 disease — Polaryx's lead LSD indication. Direct competitor in the same NCL therapeutic space with proven rare disease commercialization capabilities.
• Lexeo Therapeutics: Clinical-stage gene therapy company with LX1004 (AAV-mediated CLN2 gene therapy) — directly competes with Polaryx's PLX-200 and PLX-400 in CLN2 disease. Similar target patient population and therapeutic modality overlap.

Emerging players

• Sigilon Therapeutics: Clinical-stage company developing novel therapies for rare diseases including lysosomal storage disorders using encapsulated cell therapy and gene therapy approaches. Operates in the same rare disease treatment paradigm as Polaryx.
• IntraBio: Clinical-stage company developing repurposed drugs (including N-acetyl-L-leucine) for rare neurological diseases including LSDs. Comparable platform approach of repositioning approved compounds for rare neurodegenerative conditions.
• Passage Bio: Clinical-stage AAV gene therapy company developing treatments for rare monogenic CNS diseases including GM1 gangliosidosis. Comparable approach and target indications within the broader LSD space where Polaryx operates.
• M6P Therapeutics: Preclinical-stage company developing gene therapies for LSDs using AAV vectors and enzyme replacement approaches targeting mannose-6-phosphate receptor pathways. Comparable preclinical gene therapy focus overlapping with Polaryx's PLX-400 program.
• Azafaros: Clinical-stage company developing oral small molecule therapies for rare lysosomal storage disorders (GM1/GM2 gangliosidosis, Niemann-Pick C). Directly comparable in modality, target indication overlap, and pediatric LSD focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Polaryx777
• YouTubeyoutube.com/watch?v=SUkqLEtFFu0
• LinkedInlinkedin.com/company/hahn-jun-lee

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polaryx Therapeutics